Methylphenidate denied access to the WHO List of Essential Medicines for the second time
- 19 February 2022
- journal article
- editorial
- Published by BMJ in BMJ Evidence-Based Medicine
- Vol. 28 (2) , 75-77
Abstract
Essential medicines are those that satisfy the priority healthcare needs of the majority of the population and, as such, should be available in a functioning healthcare system at all times. This concerns the availability of appropriate dosages, amounts and quality. The costs of an essential medicine should be set at a level, which is affordable to the individual in a given community. To ensure low costs, sufficient supply and rational use of essential medicines, the World Health Organization (WHO) created the first Model List of Essential Drugs in 1977 (now Model List of Essential Medicines). The list has since then been updated 22 times, most recently in September 2021.4 The selection of a medication as an essential medicine should be based on its relevancy to disease patterns, the quality and cost-effectiveness of the medicine, its pharmacokinetics and acceptability, notwithstanding the evidence of its performance in a variety of settings as well as evidence of its efficacy and safety.5Keywords
This publication has 12 references indexed in Scilit:
- Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series studyThe Lancet Child & Adolescent Health, 2020
- Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profileBMJ Evidence-Based Medicine, 2020
- The Magic of Randomization versus the Myth of Real-World EvidenceNew England Journal of Medicine, 2020
- Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical lookBMJ Evidence-Based Medicine, 2018
- Unbalanced risk-benefit analysis of ADHD drugsThe Lancet Psychiatry, 2018
- Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysisThe Lancet Psychiatry, 2018
- Best practice in prescribing off-label medication for childrenNurse Prescribing, 2018
- Evidence on methylphenidate in children and adolescents with ADHD is in fact of ‘very low quality’Evidence Based Mental Health, 2016
- Attention-Deficit/Hyperactivity Disorder in a Chronic Care ParadigmPostgraduate Medicine, 2013
- Epidemiology of attention-deficit/hyperactivity disorder across the lifespanCurrent Opinion in Psychiatry, 2007